Barnes Alane P 4
4 · BIOCRYST PHARMACEUTICALS INC · Filed Dec 3, 2025
Insider Transaction Report
Form 4
Barnes Alane P
VP, General Counsel & Corp Sec
Transactions
- Exercise/Conversion
Common Stock
2025-12-01$3.22/sh+91,004$293,033→ 507,156 total - Sale
Common Stock
2025-12-01$7.10/sh−91,004$646,511→ 416,152 total - Sale
Common Stock
2025-12-02$7.21/sh−50,906$367,216→ 365,246 total - Sale
Common Stock
2025-12-03$7.65/sh−19,770$151,241→ 345,476 total - Exercise/Conversion
Emp. Stock Option (Right to Buy)
2025-12-01−91,004→ 0 totalExercise: $3.22From: 2017-05-23Exp: 2026-05-23→ Common Stock (91,004 underlying)
Footnotes (4)
- [F1]This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
- [F2]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.015 to $7.190. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- [F3]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.180 to $7.255. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- [F4]The option grant became exercisable at the rate of 25.0% on each of the first, second, third, and fourth anniversaries of the date of grant.